Carregant...

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma

Intravenous brentuximab vedotin (ADCETRIS(®)) is a targeted antibody-drug conjugate (ADC) active against CD30-positive cancer cells such as those associated with classical Hodgkin lymphoma (HL). In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drugs
Autor principal: Scott, Lesley J.
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7102329/
https://ncbi.nlm.nih.gov/pubmed/28190142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-017-0705-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!